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ABSTRACT
In Belgium, individual laboratory and treatment data 
of all HIV-infected patients seen in the 9 AIDS Reference 
Centres and 7 AIDS Reference Laboratories are collected 
prospectively since 2006. We present here an analysis of 
patients recorded in the cohort database between 1st of 
January 2006 and 31st of December 2008. During that 
period, 11982 patients were under medical follow-up in 
Belgium. Sixty-one percent of the patients were male and 
the median age was 39.8 at the time of first recorded viral 
load. Among the patients whose nationality or probable 
mode of transmission was recorded, nearly half (48.0%) 
were Belgian and 38.3% originated from Sub-Saharan 
Africa; heterosexual contacts were reported in the major-
ity of cases (56.0%) followed by homosexual contacts 
(35.3%). A total of 145 deaths were reported. Around 
three quarters of the patients were on ART. The median 
CD4 cell count rose from 470 cells/mm³ in 2006 to 501 
cells/mm³ in 2008. This cohort enabled us to obtain com-
prehensive information on the numbers and characteris-
tics of HIV-infected patients currently being followed up 
in Belgium, and on trends in antiretroviral therapy and 
biological results. This will serve for planning purposes, 
evaluation of access to care and as a source of informa-
tion for further studies. 
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centrum UZBrussel: Lacor P; Revalidatiecentrum Instituut voor 
Tropische Geneeskunde / Universitair Ziekenhuis Antwerpen: 
Florence E; Specifiek Revalidatiecentrum inwendige ziekten van 
de Universitaire Ziekenhuizen van de KULeuven: Van Wijn-
gaerden E; «Centre de Prise en charge», Cliniques Universitaires 
Saint-Luc, Bruxelles: Vandercam B; «Unité de Traitement des 
Immunodéficiences», Hôpital Erasme, Bruxelles: Goffard JC; Ref-
erentiecentrum van het Universitair Ziekenhuis Gent: Vogelaers 
D and Vandekerckhove L; Centre de Référence de l’Université de 
Liège: Moutschen M; «Centre Arthur Rimbaud», CHU Charleroi: 
Legrand JC; «Centre de Traitement de l’Immunodéficience», 
CHU St-Pierre, Bruxelles: De Wit S; LRS Unité de Microbiologie, 
UCL, Bruxelles: Goubau P; ARL Laboratorium voor Virologie, 
KULeuven: Van Ranst M; LRS Laboratoire de Virologie, Hôpital 
Erasme, Bruxelles: Liesnard C; ARL Laboratorium voor Microbiol-
ogie, ITG, Antwerpen: Fransen K; ARL Laboratorium voor Bacterio-
logie en Virologie, UZ Gent: Plum J; ARL Universitair Ziekenhuis 
Brussel: Pierard D; LRS Centre de Transfusion sanguine, Université 
de Liège: Gothot A; ARL Universitair Medisch Centrum Sint-Pieter: 
Van den Wijngaert S.
INTRODUCTION
Acquired immune deficiency syndrome (AIDS) and the 
human immunodeficiency virus (HIV) infection are under epi-
demiological surveillance in Belgium since 1985. The Scien-
tific Institute of Public Health (IPH) collects notifications of 
new HIV diagnoses from the AIDS Reference Laboratories and 
of new AIDS cases from clinicians (1-3). This comprehensive 
surveillance system was implemented soon after the first 
AIDS cases were reported in Belgium in 1983 and has been 
providing important information on the spread, the demo-
graphics and other characteristics including risk factors of the 
HIV epidemic in Belgium. This surveillance system does not 
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Only ARLs are mandated to carry out viral load measure-
ments and resistance tests necessary for the medical monitor-
ing of the HIV infected patients. Therefore, the number of 
patients with VL measurements reported by the ARLs pro-
vides a reliable estimate of the total number of HIV patients 
in current follow-up in Belgium.
Data collection of HIV patients in follow-up
The IPH started collecting individual routine data on HIV 
patients in follow-up from the 7 ARLs on 1st of January 2006 
and from the 9 ARCs on 1st of April 2006 (Figure 1). Data of 
all patients with at least one viral load measurement per-
formed in an ARL and/or at least one medical contact in an 
ARC since 2006 are recorded in the cohort. Once a year, all 
ARLs and ARCs transmit their data covering the period 1st of 
January - 31st of December in a standardised electronic for-
mat to the IPH.
The following information is collected: viral loads, CD4 cell 
counts, antiretroviral therapy (as of 31st of December), date of 
last medical visit during the year and death notifications.
The same coding system is used as that in the IPH’s data-
base of HIV diagnoses. In that way, demographic data and 
dates of HIV diagnosis from that database can be linked to 
the data of patients in follow-up.
Follow-up data are checked at the IPH for out-of-range 
and missing values which are reported back to the centres 
and laboratories for correction. Biological data of patients 
reported by more than one ARC or ARL during a given year 
are merged. 
Statistical analysis
All patients in follow-up in the database between 1st Jan-
uary 2006 and 31st December 2008 were included in the pre-
sent analysis. We defined the total population under follow-
up as the patients with at least 1 VL measurement recorded 
during the study period. Analyses of antiretroviral therapy 
and biological data were performed on all the patients seen 
in the ARCs between April 2006 and December 2008. For 
each year, antiretroviral therapy was defined as the treatment 
regimen on the 31st of December. Patients below 15 years of 
age were excluded from the analyses of biological data.
allow monitoring of outcomes of HIV infected patients. There 
is however a need for such information as the size of the HIV-
infected population is steadily increasing since the introduc-
tion of antiretroviral therapy and the resulting increase in life 
expectancy (4).
In several European countries, cohorts of HIV infected 
patients have already been set up. These cohorts are valuable 
sources of clinical, epidemiological and public health infor-
mation and have improved our understanding of the natural 
course of the disease and associated risk factors, as well as 
our knowledge of the effects of antiretroviral therapy. Some 
cohorts include all patients seen for care in the country (5) 
whilst others focus on patients seen in specific centres only 
(6-9). Consequently, national coverage of the HIV patient 
population and representativity of the patients included vary 
between cohorts. 
In this context, the Belgian HIV Cohort was initiated in 
2006 to obtain a more comprehensive picture of the HIV epi-
demic in Belgium. It consists of a prospective multicenter 
data collection from all seven AIDS Reference Laboratories 
(ARL) and all nine AIDS Reference Centres (ARC) in Belgium. 
The aim of this cohort is to acquire and share information on 
the characteristics of the HIV population under medical fol-
low-up and the evolution of these characteristics. The imple-
mentation of such a cohort will hopefully contribute to 
improve the management of the People Living with HIV/AIDS 
(PLWHA) in Belgium. More specifically, the objectives of the 
cohort are to estimate the number of HIV patients in follow-
up and their demographic profile, to monitor outcomes in 
terms of death and lost to follow-up and to assess immuno-
logical (CD4) and virological (VL) changes over time, as well 
as antiretroviral therapy (ART) uptake.
In this article we describe the design features of the Bel-
gian HIV Cohort and present selected demographic, labora-
tory and treatment characteristics of the HIV patients under 
medical follow-up in Belgium from 2006 to 2008.
METHODS
National surveillance of HIV diagnoses
Screening HIV tests can be performed in any clinical biol-
ogy laboratory in Belgium.
However, samples that test positive have to be sent for 
confirmation to one of the 7 ARLs that will perform further 
screening tests and immunoblots. These ARLs are officially 
recognised by the Belgian social security body, the National 
Institute of Sickness and Invalidity Insurance (INAMI/RIZIV). In 
case of a new confirmed diagnosis of HIV infection, data on 
age, sex, nationality, residence, sexual orientation, probable 
mode of HIV transmission and CD4 cell count at the time of 
HIV diagnosis are collected from the treating physician. These 
data are then sent by the ARLs to the IPH and included in the 
database of HIV diagnoses.
HIV patients care system in Belgium
The INAMI/RIZIV also officially recognizes nine ARCs that 
are specialised in the management of HIV infected patients, 
which includes clinical care and psychosocial support. HIV-
positive patients can either attend one of the ARCs, other clin-
ics specialised in HIV care or be seen by a general practitioner. Figure 1: Data collection flow for HIV patients in Belgium.
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reverse transcriptase inhibitors (NNRTI) decreased slightly, 
whereas the proportion on protease inhibitors (PI) increased, 
particularly those on lopinavir/ritonavir (20.9% in 2007 and 
23.2% in 2008).
Biological results
The latest CD4 cell counts and VL measurements in each 
year of follow-up are presented in Table 3. Around 80% of the 
patients had at least 2 CD4 cell counts and 2 VL measurements 
per year. Median CD4 count rose over the years (470 cells/mm³ 
in 2006 to 501 cells/mm³ in 2008) and the proportion of 
patients with CD4 counts < 200 cells/mm³ decreased from 
9.3% in 2006 to 6.2% in 2008. At the same time, the proportion 
of patients with VL > 1.7 log copies/ml decreased from 41.2% 
in 2006 to 34.5% in 2008. For both parameters, the changes 
were particularly pronounced among those on ART. Some of 
Proportions or medians with interquartile ranges were 
calculated for all variables. Comparisons between the patients 
lost to follow-up and the others were made with chi-square 
and Kruskal-Wallis tests. P-values of less than 0.05 were con-
sidered statistically significant. Analyses were performed with 
Stata version 10 (StataCorp, College Station, Texas, USA).
RESULTS
Population characteristics
Since 1985 up to the 31st of December 2008, 22243 per-
sons were diagnosed with HIV infection in Belgium. 
Between January 2006 and December 2008, a total of 
11982 patients were under medical follow-up. The number of 
patients increased from 8583 patients in 2006 to 9351 in 2007 
and 10071 in 2008. Sixty-one percent of the 11982 patients 
were male. The median (IQR) age at the first recorded VL after 
the 1st of January 2006 was 41.4 (34.2-48.2) years for men and 
37.2 (30.4-44.1) years for women (Figure 2). Two percent of 
the patients were less than 15 years old.
Of the patients whose nationality was recorded, nearly 
half (48.0%) had the Belgian nationality and 38.3% were from 
Sub-Saharan Africa (Table 1). Among those with available 
data on probable mode of transmission, heterosexual contact 
was reported in the majority of cases (56.0%) while sexual 
intercourse between men was the probable mode of trans-
mission in 35.3% of cases; intravenous drug use (IDU) was 
reported by 3.3% of patients only. More than half of the 
patients (63.7%) were diagnosed with HIV from 2000 onwards, 
30.0% between 1990 and 1999 and 6.3% before 1990.
Out of the 11982 patients in care, 9071 (75.7%) HIV 
patients were followed up in the nine ARCs. Among these 
patients, 145 deaths were reported. 
Antiretroviral therapy
Nearly three quarters of the patients were on ART (Table 2). 
Among them more than 97% were receiving at least 3 differ-
ent ARV drugs. The proportion receiving nucleoside/nucleo-
tide reverse transcriptase inhibitors (NRTI) remained stable 
over the years. The proportion of patients on non-nucleoside 
Figure 2: Age and gender distribution of the HIV patients in medical 
follow-up in Belgium, 2006-2008.
Table 1: Characteristics of the HIV patients in medical 








































































a Other: transfusion recipients and persons with haemophilia.
Table 2: Exposure to different classes of ARV drugs among 
HIV patients of the Belgian ARCs, 2006-2008
2006 2007 2008
Population * 6651 7063 7730
ART status:
 on ART: n (%)
 not on ART: n (%)













≥ 3 ARV drugs: % 97.4% 97.3% 97.8%
NRTI: % 98.5% 98.2% 98.1%
PI: % 49.4% 53.0% 54.1%
NNRTI: % 47.6% 46.6% 46.9%
* Excluding patients followed in more than one ARC or deceased.
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A large majority of the patients were seen in ARCs. Nearly 
three quarters of them were on treatment with at least 3 dif-
ferent antiretroviral drugs. In 2 other cohorts in the Nether-
lands and Switzerland (10, 11), around 80% of the patients 
were reported to be on ART. The proportion of patients on 
ART is influenced by the characteristics of the patients 
included in each cohort such as disease stage. For instance 
the Swiss HIV Cohort Study reported that AIDS patients were 
better represented in the cohort than in the patients reported 
by the Federal Office of Public Health (13).
An increase in the use of PIs, particularly lopinavir/ritona-
vir, was observed during the study period. Both PIs or NNRTIs 
in combination with 2 NRTIs are recommended by the Euro-
pean AIDS Clinical Society as first line therapy in treatment 
naïve HIV-infected patients (14). The observed increase could 
be due to the preference for PI-based regimens for therapy 
initiation in some cases using the argument of their higher 
genetic barrier to resistance. The proportion of patients on 
second line therapy with regimens including a PI may also 
have increased, seeing the aging of the HIV-infected popula-
tion and the need to switch therapy for various reasons at 
some point in the ‘treatment life’ of a patient. Other factors 
such as drug characteristics may have influenced the choice 
of ART by clinicians (15). For instance, availability of lopinavir/
ritonavir in combination tablets, the fact that it could be kept 
outside the refrigerator and the small number of pills can 
probably explain its preferential use among the available PIs 
at the time. The choice of antiretroviral drug can also be influ-
enced by drug availability and reimbursement conditions in 
Belgium; these are constantly evolving and will surely influ-
ence the antiretroviral drugs used in the following years.
More than 80% of patients had at least 2 laboratory fol-
low-up measurements performed per year. In the coming 
years, we may see a decrease in the number of VLs per year 
for patients on a stable and fully suppressive combination 
antiretroviral therapy, as suggested in a recent article by 
Reekie et al (16). But this may be balanced out by the more 
frequent VLs asked for patients more virologically unstable or 
just starting on ART.
Several determinants could explain the observed increase 
in median CD4 values of the patients over the years. Firstly, an 
evolution towards earlier diagnosis of HIV-infection with higher 
CD4 counts at diagnosis has been observed in Belgium (2). Sec-
ondly, ART initiation may take place at higher levels of CD4 
counts, following the recent treatment recommendations 
towards earlier therapy initiation (14, 17-19). Changes in guide-
lines have indeed been described to have an influence on the 
timing of ART initiation (20). Thirdly, a better adherence to 
treatment thanks to better tolerated, easier to use and more 
potent drugs could also have had an impact on CD4 values. 
A corresponding decreasing trend in the proportion of patients 
with CD4 cells below 200 cells/mm³ - patients at higher risk of 
death - was observed between 2006 and 2008. 
One of the strengths of this cohort is that the general char-
acteristics of the HIV patients presented here are representative 
of all HIV patients in Belgium. Indeed all viral load assays are 
performed in the ARLs, with the exception of a few patients 
enrolled in some pharmaceutical trials or whose biological anal-
yses are performed abroad. On the other hand, information on 
ARV treatments and CD4 cell counts was collected only from 
the ARCs and VL data were analysed only for those patients. 
the patients may have had their treatment modified between 
the time of last laboratory measurement and the time of treat-
ment recording at the end of the year.
DISCUSSION
Nearly 12000 HIV-infected patients were in medical fol-
low-up in Belgium between 2006 and 2008. This number 
increased every year.
Compared to HIV patients followed in neighbouring coun-
tries (6, 10,11) patients in the Belgian cohort are  characterised 
by a large proportion of women and a large proportion of 
patients from sub-Saharan Africa. This is reflected in the main 
mode of transmission which is sexual intercourse between men 
and women. These features are similar to the characteristics of 
the new diagnoses of HIV infection in Belgium (2): they show a 
predominance of the heterosexual mode of transmission and a 
high proportion of migrants from sub-Saharan Africa. However, 
the proportion of MSM among the newly diagnosed individuals 
has sharply increased over the last years (from 23.2% in 2002 to 
45.9% in 2008) (12). Consequently a slight increase in the num-
ber of MSM patients in follow-up (28.4% in 2006 and 29.8% in 
2008) is observed. 
Table 3: CD4 counts and viral loads among HIV patients of 
the Belgian ARCs, 2006-2008
  2006 2007 2008
CD4 counts
% with > 1 CD4 count per year
in patients not on ART N/A 71.4% 71.8%
in patients on ART N/A 87.8% 86.7%
in all patients N/A 82.8% 82.9%
Latest CD4 count value in year
 Median [IQR]  cells/mm³


















 Proportion < 200 cells/mm³
in patients not on ART 5.3% 3.2% 3.7%
in patients on ART 10.6% 8.0% 7.1%
 in all patients 9.3% 7.0% 6.2%
VL measurements    
% with > 1 VL measurement per year
in patients not on ART N/A 65.3% 72.7%
in patients on ART N/A 83.9% 91.2%
in all patients N/A 78.0% 86.6%
Latest VL result in year
 Proportion > 1.7 log copies/ml
in patients not on ART 90.7% 94.5% 92.3%
in patients on ART 24.5% 16.2% 16.0%
 in all patients 41.2% 35.4% 34.5%
N/A: not available.
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Patients followed in other medical centres than the ARCs tend 
to be slightly younger, more likely to be of non-Belgian nation-
ality and to be more recently diagnosed with HIV than ARC 
patients. Given that these differences could have an impact on 
therapy and biological results, we cannot generalise the infor-
mation on ART nor apply our biological findings to all the Bel-
gian HIV patients. Nevertheless the patients seen in ARCs do 
represent ¾ of all HIV-infected patients under follow-up.
In conclusion, the implementation of this cohort has ena-
bled us to obtain comprehensive data on the number and 
characteristics of HIV-infected patients currently being fol-
lowed up in Belgium. It provided us with information on 
trends in antiretroviral therapy and biological results for more 
than three quarters of the seropositive patients under care. 
Such data should be of help for planning future needs in 
terms of treatment and laboratory follow-up. It could also 
prove useful to evaluate access to care of HIV-infected 
patients. Finally, the cohort will be a valuable source of data 
to support other specific studies. 
ACKNOWLEDGEMENTS
We would like to warmly thank all the people involved in 
the data collection in the ARCs and ARLs. This work was 
funded by the National Institute of Sickness and Invalidity 
Insurance (INAMI/RIZIV).
CONFLICT OF INTEREST: None.
REFERENCES
 1. Infuso A, Hamers F, Downs AM, Alix J. HIV reporting in western Europe: national 
systems and first European data. Euro Surveill 2000; 5(2): 13-17.
 2. Sasse A., Verbrugge R., Buzarsist J., Van Beckhoven D. Epidémiologie du SIDA et 
de l’infection à VIH en Belgique: Situation au 31 décembre 2009. Brussels: Sci-
entific Institute of Public Health; 2010.
